Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Jan
23
Today In Oncology
HCC LLM Advice and Treatment Concordance
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo